Bates White client Johnson & Johnson (J&J) received a favorable summary judgment ruling in September 2026 in a False Claims Act qui tam litigation matter. In this matter, the Relator alleged that J&J (formerly Janssen Biotech) violated the Anti-Kickback Statute by advising doctors how to establish in-office infusion centers in order to incentivize them to prescribe and administer Janssen’s infused drugs Remicade and Simponi ARIA.

Bates White supported Brian E. Harvey, MD, PhD, who served as a clinical and regulatory expert on behalf of Janssen. Dr. Harvey spent 11 years at the Food and Drug Administration (FDA), including as the Gastroenterology Medical Officer on the agency team responsible for reviewing Remicade’s original BLA submission and as Director of the Gastroenterology Products Division, where he was the signatory authority for several Remicade sBLA approvals. Dr. Harvey submitted a report that discussed treatment considerations for inflammatory diseases and the impact of Remicade’s introduction on the clinical standard of care for modern-day patient treatment practices for Crohn’s Disease. His report was based upon the medical literature, clinical trial study results, publicly available FDA review documents, and his medical training in gastroenterology.

Kathleen Chandler and Sam Cohen supported Dr. Harvey in this matter.

The team

The team also includes

Related practices and specialties

Jump to Page

Get in touch.

Partner with a firm that delivers rigorous economic research and practical advice.